Biotech
Upstream Bio
Upstream Bio raises $153M Series B at $800M valuation
Waltham, MASeptember 10, 20241 min read
Total Raised
$153M
Valuation
$800M
Latest Round
Series B
Employees
120+
Upstream Bio: Series B Funding Round
Upstream Bio has successfully raised $153M in Series B funding, reaching a valuation of $800M.
Company Overview
Developing antibody therapeutics for inflammatory diseases
Funding Details
The Series B round was led by Fidelity, with participation from Viking Global.
Company Information
- Headquarters: Waltham, MA
- Founded: 2020
- Employees: 120+
- Category: Biotech
Investment
Upstream Bio plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Fidelity: Verified investor in Series B
- Viking Global: Verified investor in Series B
Company Info
Headquarters
Waltham, MA
Founded
2020
Team Size
120+
Last Round
$153M(Sep 2024)
Investors (2)
F
FidelityLeadLead Investor
Verified investor in Series B
V
Viking GlobalInvestor
Verified investor in Series B
Share
Related Reports
Biotech
AusperBio
AusperBio Raises $73M Series B
Biotech company developing AHB-137, an antisense oligonucleotide for chronic hepatitis B treatment entering phase 2 trials
David Chen
Dec 30, 2025
0 min read•$73M Series B
Biotech
Orna Therapeutics
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Emma Rodriguez
Oct 23, 2025
0 min read•$251M Series B
Biotech
Forge Biologics
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Sarah Kim
Oct 23, 2025
0 min read•$120M Series C
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free